{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:34:49Z","timestamp":1784334889803,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.amjcard.2024.02.039","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:10:25Z","timestamp":1709287825000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-782X","authenticated-orcid":false,"given":"Sahib","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-9756","authenticated-orcid":false,"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.02.039_bib0001","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2024.02.039_bib0003","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0004","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0005","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0006","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/M22-2904","article-title":"Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update","volume":"176","author":"Navaneethan","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0008","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0009","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacasi.2022.03.009","article-title":"Clinical benefits of sodium-glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects","volume":"2","author":"Kubota","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National trends in use of sodium-glucose Cotransporter-2 inhibitors and glucagon-like Peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0011","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00228-023-03539-8","article-title":"Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014\u20132022)","volume":"79","author":"Lin","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0014","unstructured":"Review Manager. Vol. 5 (RevMan 5) [Computer program]. version 5.4. Copenhagen: The Cochrane Collaboration; 2020."},{"key":"10.1016\/j.amjcard.2024.02.039_bib0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0016","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0017","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0019","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/jcm11102935","article-title":"Dapagliflozin impact on the exercise capacity of non-diabetic heart failure with reduced ejection fraction patients","volume":"11","author":"Reis","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0020","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0021","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium-glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060655","article-title":"Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"12","author":"Tsai","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295059","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: a systematic review and meta-analysis","volume":"18","author":"Reyes-Farias","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2024.02.039_bib0024","unstructured":"SGLT2 for Heart Failure in CHD Patients. Identifier: NCT05897489. Available at: ClinicalTrials.gov. Accessed on December 10, 2023."},{"key":"10.1016\/j.amjcard.2024.02.039_bib0025","unstructured":"Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients. Identifier: NCT05914857. Available at: ClinicalTrials.gov. Accessed on December 10, 2023."},{"key":"10.1016\/j.amjcard.2024.02.039_bib0026","unstructured":"Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY). Identifier: NCT05776043. Available at: ClinicalTrials.gov. Accessed December 10, 2023."},{"key":"10.1016\/j.amjcard.2024.02.039_bib0027","unstructured":"Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients. Identifier: NCT05335629. Available at: ClinicalTrials.gov. Accessed December 10, 2023."},{"key":"10.1016\/j.amjcard.2024.02.039_bib0028","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am Heart J Plus"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:12:29Z","timestamp":1731071549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"alternative-id":["S0002914924001619"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.02.039","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.02.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}